Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Table 4 Least-squares (LS) mean (SE) change from baseline in prolactin levels (ng/ml) at end point

Variable	Placebo, n = 83	Paliperidone palmitate
		234/39 mg, n = 72	234/156 mg, n = 72	234/234 mg, n = 85
Males
n	56	50	46	60
Baseline, mean (SD)	31.7 (21.1)	28.7 (21.2)	30.2 (25.2)	28.4 (19.0)
LS mean (SE) change from baseline	-25.0 (4.1)	1.3 (3.9)	0.6 (4.1)	2.6 (3.9)
P value for LS mean (vs placebo)	--	<0.001	<0.001	<0.001
Females
n	27	22	25	25
Baseline, mean (SD)	81.8 (50.9)	76.2 (53.0)	85.7 (56.3)	80.0 (67.8)
LS mean (SE) change from baseline	-45.9 (17.1)	17.8 (16.3)	17.8 (16.8)	42.9 (17.9)
P value for LS mean (vs placebo)	--	0.001	<0.001	<0.001

Each paliperidone palmitate subject received 234 mg of paliperidone palmitate on day 1 and then their assigned dose day 8 and monthly thereafter.

ISSN: 1744-859X